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Abstract 
Background :To find out ovulation rates, in 
Clomiphene citrate (CC) resistance anovulatory 
infertility, after administration of human 
menopausal gonadotrophin. 
Methods:  In this cross sectional study  400 infertile 
patients of  anovulation, bilateral patent fallopian 
tubes evidenced by HSG, normal husband semen 
analysis and resistant  to Clomiphene citrate therapy 
and take at least three months consecutive 
unsuccessful treatment in dose >150 mg/day were 
incorporated. Patients were divided randomly via 
lottery technique into two groups. Group-A, 
included those subjects who received Clomiphene 
citrate (CC) daily from day 2 to 6 of menstrual cycle 
and Human Menopausal Gonadotrophin 75 IU 
begun from day 7 onward for 3 days intramuscularly. 
Group B comprised of those who received Human 
Menopausal Gonadotrophin alone 75 IU 
intramuscularly begun from day 2 of menstrual 
cycle, 5 injections were given on alternate day till 
10th day of cycle. Follow up was done by ultrasound 
for follicle tracking and serum progesterone level on 
day 21 of the treatment cycle.  
Results:  Mean age was 30.12±4.8 years and 
30.27±4.48 years in both groups respectively without 
significant difference. Out of 400 patients, ovulation 
induction was observed in 386 patients of both 
groups. Among these 386, 15 patients got pregnant, 
9(2.25%) from group A and 6(1.5%) from group B. 
Mild OHSS was seen in 12 (3%) and moderate OHSS 
was seen 4 (1%). 
Conclusion:  Clomiphene Citrate with Human 
Menopausal Gonadotropins have a likely supportive 
consequences on ovulation rate contrasted to that of 
Human Menopausal Gonadotropin alone. 
Key words: Ovulation Induction, Clomiphene 
Citrate Resistance, HMG 
Introduction 
Infertility is the important health issue that has 
physical and emotional effects, and that affects 8–10% 
of women and men at reproductive age.1 Even though 
infertility itself can not affect physical well-being, it 
can possibly have a serious influence on the social and 
mental health of couples as well as can cause social 
and detrimental consequences for example ostracism 
and divorce. A worldwide review of infertility from 
the world fertility analysis and others projected alike 
proportions of infertility are, 6%, 5%, 4%, and 4% 
within South Asia, Nepal, Pakistan, Bangladesh, and 
Sri lanka, respectively.2 
Infertility represents a rising medical challenge. A 
progressive reduction in fertility rates (number of live 
births to the total population of females at 
reproductive ages) has been indicated since 1955 and 
that of within the same age group.3The decrease in 
fertility rate is correlated with both the non-medical 
and medical factors. Female age is a key factor of an 
average time period needed to conceive among all 
couples in addition particularly in the couples who 
have delayed conception until the female reaches her 
mid-thirties. The greatest live birth rates are among 
the 20-30 years of age group and drops sharply 
following 35 years of age. Moreover, the infertility 
duration plays a role in significant information to 
approximate the upcoming fertility, since every year of 
infertility significantly diminishes the chance of birth.4 
In addition, the more the time period of infertility, the 
higher the probability of the presence of genetic or 
more severe pathological factors. Ovulatory 
dysfunction is frequent factor of women infertility, 
taking place among around 40% of infertile females. 
Unfortunately still among about 20% of couples, the 
infertility factor remain unidentified.1 
Like the rest of the world, treating infertility poses 
problems in Pakistan also. It is a challenge to the 
professionals more, because in our social setup an 
infertile woman has to face many social problems as 
well.5 Most of the subjects delay looking for the advice 
from an expert till they reach their late 30s and 40s. 
The desire of the children by a normal woman is 
stronger than self-interest in beauty, figure and the 
claims of a career. In nearly all cases, the wives are the 
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first to approach a physician, as there is a false concept 
that sexual strength of a male is equal to fertility.5  
Being unable to conceive due to ovulation dysfunction 
causes several females to use ovulation induction 
treatment to handle their ovulatory infertility. 
Ovulation induction is the stimulation of ovulation by 
medication.6 Ovulation induction treatment is an 
infertility therapy that lets females to ovulate and 
achieve a chance to conceive naturally. This therapy 
stimulates the ovaries to yield a single mature 
(dominant) follicle, to stimulate ovulation, and to let 
fertilization and pregnancy takes place via natural 
intercourse.6 Approaches to ovulation induction 
therapy may include ovulation induction drug therapy 
(alone or in combination with further interventions 
and/or drug therapies) or surgeries.6 A treatment plan 
for infertility requires an understanding of etiology of 
the disorder and the natural history of the condition to 
reach a diagnosis and to start treatment. Hormonal 
treatment is safe, useful, and effective for the 
treatment of infertility. Various hormonal therapy 
protocols have been practiced for ovulation induction, 
in addition to Clomiphene citrate, hMG, GnRH, 
Insulin sensitizers, Aromatase inhibitor, alone or in 
combination. This study has been conducted to find 
out ovulation rates, in Clomiphene citrate (CC) 
resistance anovulatory infertility, after administration 
of human menopausal gonadotrophin. 
 
Patients and Methods 
This randomized clinical trial was held at the 
outpatient department of PUMHS, from November 
2013 to October 2015.  All the women with 
primary/secondary infertility due to anovulation, 
bilateral patent fallopian tubes evidence by HSG, 
normal husband semen analysis and patients with 
documented anovulation who were  resistant to 
clomiphene citrate therapy and take at least three 
months consecutive unsuccessful treatment in dose 
>150 mg/day were included in the study. All the 
women with any pelvic pathology like endometriosis, 
fibroid uterus, and ovarian pathology (Excluding 
PCOS), tubal pathology/ obstruction, malformation of 
sexual organ incompatible with pregnancy and 
hypersensitivity to any trial product were excluded.  
Women were instructed to bring their husbands along 
with them. These patients were investigated for 
routine including husband semen analysis, hysteron-
salpingography and ultrasonography. In women who 
did not have spontaneous menstrual cycle, withdrawal 
bleeding was induced by administering oral 
medroxyprogesterone acetate 5 mg twice daily for 5 
days. All these women had both ultrasound and 
endocrine assessment by hormonal assay (LH, FSH, 
S.Prolactin) done prior to the beginning of treatment. 
Those patients who had previously failed to conceive 
or ovulate on clomiphene up to a dose of 150 mg daily 
for five days were included in the study. Patients were 
divided by lottery method into two groups according 
to treatment as:Patient’ s of Group A received CC 
daily from day 2 to 6 days of menstrual cycle with 
combination Human Menopausal Gonadotrophin 75 
IU begun from day 7 onward for 3 days 
intramuscularly. Women in Group B received Human 
Menopausal Gonadotrophin 75 IU intramuscularly 
begun from day 2 of menstrual cycle, 5 injections were 
given on alternate day till 10th day of cycle. Monitoring 
was carried out by follicle measurement using TVS on 
day 12-16 in group A and on alternate day from day 10 
– 16 in group B in collaboration with ultrasound 
department. The stimulating medication was stopped 
and human chorionic gonadotropin (hCG) was 
administered intramuscularly to induce ovulation, 
once the leading follicle was 14-20 mm. All patients 
were advised to do timed intercourse in between day 
10 to 20. Serum progesterone was done on day 21 of 
the treatment cycle in both groups for the confirmation 
of ovulation. A urine pregnancy test was performed if 
the expected menstrual cycle was delayed. All the data 
was entered in the proforma. Mean +SD was 
calculated for quantitative variable like age, duration 
of marriage, duration of infertility, height, weight, 
BMI, Hemoglobin, BSR.  Chi-square test was applied 
for comparison categorical variables and t-test was 
applied for comparison of mean and standard 
deviation in both groups. P-value<0.05 was considered 
as significant. 
 
Results 
In this study 400 females with infertility were taken for 
the purpose of ovulation. Mean age was 30.12±4.8 
years and 30.27±4.48 years in both groups respectively 
( p-value = 0.739;insignificant).   In group A the mean 
duration of marriage was 5.81 ± 3.80 years and in 
Group B the mean duration of marriage was 5.83 ± 
3.06 years(p-value = 0.957;insignificant). Primary 
infertility was significantly high in group B and 
secondary infertility was higher in group A(p-value = 
0.002). The mean duration of infertility in group A was 
4.93 ± 3.13 years and in Group B 5.41 ± 2.97 years. 
Dysmenorrhea was seen in 40 cases were from group 
A and 56 were from group B( p-value = 0.07). Breast 
tenderness was in 34 cases from group A and 42 in 
group B. In group A, galactorrhea was present in 26 
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females which was significantly higher  from group B 
(p-value = 0.028).  
Table  1: Patients distribution according to  
demographic characteristics among study 
groups (n=400) 
 
Study Groups 
t-test 
Chi- 
square 
P-
value A B 
Aage (Years) 
Mean ± SD 30.12±4.80 30.27±4.48 0.334  0.739 
Residential Area 
Urban 128 139 
 1.36 0.243 
Rural 72 61 
Duration of Marriage  
Mean ± SD 5.81±3.80 5.83±3.06 0.054  0.957 
Types of Infertility  
Primary 125 154 
 9.655 0.002 
Secondary 75 46 
Duration of Infertility  
Mean ± SD 4.93±3.13 5.41±2.97 1.594  0.112 
Dysmenorrhea Frequency 
Yes 40 56 
 3.50 0.07 
No 160 144 
Breast Tenderness 
Yes 34 42 
 1.04 0.308 
No 166 158 
Galactorrhea 
Yes 26 13 
 4.80 0.028 
No 174 187 
Hirsutism 
Yes 42 53 
 1.67 0.196 
No 158 147 
Body Mass Index 
Under 
weight 
15 14 
 3.84 0.278 
Normal 
weight 
119 106 
Over 
weight 
42 59 
Obese 24 21 
Group A: Clomiphene citrate plus human 
menopausal gonadotrophin;Group B:Human menopausal 
gonadotrophin 
 
Hirsutism was seen in 42 females in group A, and 53 
females in group B. There were 15 females in group A 
and 14 females in group B who were under weight, 
119 in group A and 106 in group B had normal weight, 
101 (42 in group A and 59 in group B) were 
overweight and 45 (24 in group A and 21 in group B) 
were obese. In both study groups the status of BMI 
was statistically insignificant, p-value 0.278 (Table 1). 
 
Table  2: Patients distribution according to 
investigation among study groups   (n=400) 
 
Study Groups 
t-test 
Chi- 
square 
P-
value A B 
Bimanual Vaginal Examination 
Normal 136 138 
 0.055 0.793 
Normal with 
other findings 
51 49 
Normal with 
discharge 
13 13 
Haemoglobin 
Mean ± Std. 
Deviation 
10.93±1.33 11.14±1.41 0.043  0.118 
Ultrasound findings 
Normal 162 143 
 6.58 0.086 
PCO 34 51 
Normal with 
tubal factor 
3 6 
Others 1 0 
Signs and symptoms in PCO  cases 
Dysmenorrhea 13 27 
 3.47 0.082 
Breast 
tenderness 
12 19 
Galactorrhea 12 11 
Hirsutism 19 36 
Hoarseness of 
voice 
0 0 
Obese 3 3 
Multiple  4 2 
Group A: Clomiphene citrate plus human 
menopausal gonadotrophin;Group B:Human menopausal 
gonadotrophin 
 
According to bimanual vaginal examination, 136 cases 
of group A and 138 cases from group B had normal 
findings. On ultrasonography 305 patients had normal 
findings, in which 162 were from group A and 143 
were from group B. PCO was found in 85 females in 
which 34 were from group A and 51 were from group 
B. Normal findings with tubal factors were found in 9 
patients only (3 were from group A and 6 were from 
group B). Findings on USG were similar in both study 
groups(p-value = 0.086) (Table 2).After treatment, 197 
out of 200 had ovulation in group A and 189 in group 
B. There were 11 females in group B and 3 females in 
group A who did not have  ovulation. Group A had 
significantly more ovulation as compared to group B, 
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p-value = 0.030. Ovarian hyper stimulation syndrome 
was not developed in 384 females, 194 from group A 
and 190 from group B. Mild ovarian hyper stimulation 
syndrome was in 5 females of group A and 7 of group 
B, moderate ovarian hyper stimulation syndrome was 
seen in 4 females only, in which 1 was from group A 
and 3 were from group B. This ovarian difference was 
insignificant(p-value = 0.503) (Table 3).Fifteen females 
achieved pregnancies, 9 female of group A and 6 of 
group B and frequency of pregnancy in both study 
group was statistically non-significant, p-value = 0.433 
(Table 3). 
 
Table  3: Patient distribution according to 
outcome among study groups.  (n=400) 
 
Study Groups Chi- 
square 
P-value 
A B 
Ovulation 
Yes 197 189 
4.73 0.030 
No 3 11 
Ovarian hyper stimulation syndrome 
No 194 190 
1.375 0.503 Mild 5 7 
Moderate 1 3 
Pregnancy 
Yes 9 6 
0.623 0.433 
No 191 194 
Group A: Clomiphene citrate plus human 
menopausal gonadotrophin;Group B:Human menopausal 
gonadotrophin 
Discussion 
Infertility is the frequent clinical challenge. It 
influences 13% to 15% of couples  around world. The 
incidence differs widely, being less within developed 
nations and more within underdeveloped nations 
where there are limited resources for treatment and 
investigation.7 In current study Human menopausal 
gonadotrophin and clomiphene citrate were used 
which are economical and easily available. Human 
menopausal gonadotrophin alone and Human 
menopausal gonadotrophin plus Clomiphene citrate 
were used for ovulation induction. Total 386 patients 
showed ovulation induction. The ovulation rate was 
47.25% in Human menopausal gonadotrophin group 
and 49.25% in Clomiphene citrate plus Human 
menopausal gonadotrophin group. Fourteen patients 
did not show ovulation after treatment. Among those 
14 patients 5 were over 35 years of age and remaining 
9 had PCO. The average age of the subjects in current 
study was 30 years. Approximately 35% of the patients 
had presented at the age 35 years. Since likelihoods of 
conception decline dramatically following this age, 
this study reflects the mindfulness of the general 
population about the importance of age in infertility. 
Furthermore, the factors of infertility among older 
females are not similar to those among younger 
females. The growing age poses an adverse impact on 
every treatment modality for infertility however 
noticeably cannot be overcome.  Maheshwari A, 
proved in his study that patients with age of 35 years 
are almost twofold as likely to present with 
unexplained infertility than those younger.8  Sadia S  
presents this relationship of age and fertility. In her 
study around 90% of the  subjects had presented at the 
age of 35 years with the complaint of infertility.9  A 
study from Auckland, reported that significant impact 
of the deferral in childbearing is a rise in unexplained 
infertility associated with natural drop in monthly 
fecundity rate with age from around 25% at 25 years of 
age to 16% at the age of 35 years and 6% at the age of 
40 years.9  Whereas woman age is possibly the most 
significant single cause influencing fertility, maternal 
weight as well appears to pose a significant effect. 
Obese females are less fertile with both, by ovulation 
induction and  in natural cycles and have greater rates 
of miscarriage in contrast to their corresponding 
person of normal weight, they also need higher 
dosages of ovulation-inducing agents. 10 
In this study nine patients who did not ovulate during 
present study period had poly cystic ovaries (PCO), 
out of those 5 patients were obese and had BMI >25. 
Overweight and obesity are frequent characters among 
the PCOS cases and they have several health effects, 
together with reproductive disorders. Obese PCOS 
females are further likely to undergo infertility 
contrasted to normal-weight PCOS cases.  Balen AH et 
al studied relationship of body mass index  and 
fertility in PCOS and found that sterility rate is around 
40% greater among females with a BMI >30 contrasted 
to the females with a BMI <30 in all PCOS patients.11 
Mulders et al presented in his study that patients 
having further severe PCOS for instance polycystic 
ovaries, hyperandrogenism and obesity are low 
responders of treatment, as compared with mild 
PCOS. 12 The systematic review of Maheshwari et al, 
looked at the cycle cancellations within overweight 
and obese females and proposes that the likelihoods of 
cycle cancellation within females with BMI >25 kg/m 2 
was 1.83 as contrasted to females with BMI <25 
kg/m2.. 13 
Susanne Hahn reported in his study that significantly 
higher proportion of females having PCOS were 
clinically obese, having a raised mean BMI. He 
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performed his study on 120 women, 33 cases 
presented with BMI  24.9 kg/m2, 24 cases with BMI 
from 25 to 29.9 kg/m2 and 63 cases with BMI 30 
kg/m2. Serum testosterone, LH/FSH ratio, and mean 
hirsutism score and parameters   resistance were as 
well substantially raised in cases with PCOS. 14 A 
higher rate of PCOS case reported at present have an 
unsatisfied desire to conceive a baby but this is not 
true in case of present study as there were total 85 
PCO patient included in study and only 9 out of them 
did not show ovulation induction.  Gurnee I.L’s study 
supports present study results, which showed that the 
chances of getting pregnant with PCOS using 
infertility treatment in the form of gonadotrophin is 
very good and most of cases with PCOS will be able to 
have a baby with infertility treatment. 15 
  The successful therapy for insulin resistance and 
obesity has a potential to reverse the deleterious 
consequences of these complications. Further 
gonadotrophins are needed to accomplish ovulation 
within PCOS insulin-resistant females.16 
In current study the pregnancy rates within group A 
was noted to be greater than in group B. The clinical 
pregnancy rates were 3.75% in present study.  Shiuli 
Mukherjee et al17 also reported that the pregnancy rate 
in Clomiphene citrate + Human menopausal 
gonadotrophin was found to be significantly higher. 
This is highly consistent with few further studies that 
have contrasted Clomiphene citrate+ hMG with hMG. 
The pregnancy rates per case in Clomiphene 
citrate+hMG was considerably higher in their study 
than in hMG group (46% vs 25.9%) as was the 
pregnancy rates per therapy cycle (31.3% vs 15.8%).17 
In present study the pregnancy rate was1.5% in hMG 
group and 2.25% in Clomiphene citrate plus hMG 
group. In this study, pregnancy rate per cycle 
Clomiphene citrate +hMG  (2.25%) was lower, 
compared to those stated by Ransom et al. (9.1%).18 
Mulders A.G.M.G.J., showed successful outcome after 
gonadotrophin treatment of ovulation induction, the 
pregnancy rates were 15% per cycle as well as 41% per 
case. 19 Clomiphene citrate indirectly induces GnRH 
secretion that escalates the both LH and FSH release. 
This rise in LH, whose basal level is frequently already 
high among females with PCOS, can possibly settle 
pregnancy rates among those getting Clomiphene 
citrate .Addition of gonadotrophin with Clomiphene 
citrate can invalidate the detrimental influence of LH 
on pregnancy as well as miscarriage, and thus raises 
the pregnancy rates among PCOS females. Our 
examination has made the both ends meet by elevating 
the rates of pregnancy upto 12.7% and diminishing the 
miscarriage rates though not significant. Ziadeh  et al 
shared his experience in terms of pregnancy loss, 
which in Group A(Human menopausal gonadotrophin 
+ clomiphene citrate) was lower than in Group 
B(Human menopausal gonadotrophin) (17% vs 
33.3%).19 
In current study we have found optimal pregnancy 
rates. Those patients who respond to treatment were 
monitored with Progesterone levels and successful 
conceptions usually occurred early in the treatment 
cycles as shown in result. Fifteen females achieved  
their pregnancy, five pregnancies went to term 
uneventfully and the healthy alive babies were 
delivered. Four patients had ectopic tubal pregnancies, 
three out of these four were ruptured and one had 
intact tubal pregnancy and presented in emergency 
with pain these patients underwent salpingectomy. 
Five patients had incomplete abortion at first trimester. 
These patients presented in emergency with heavy 
bleeding per vagina. On their per vaginal examination 
product of conception was found, evacuation and 
curettage was done. The product of conception was 
confirmed on histopathology of the specimen. . The 
primary objective of ovulation induction is to support 
the maturation, recruitment, and development of just 
one or two pre-ovulatory follicles. Cases with a 
polycystic-ovary presentation have a raised inclination 
to hyper-respond to gonadotrophin therapy. Iatrogenic 
multiple gestation and ovarian hyperstimulation 
syndrome are one of the utmost serious risk factors 
correlated with gonadotrophin.In current study there 
was no case of multiple gestations. This can possibly 
be because of the fact that cycles beside excessive 
ovarian response were held as well as no hCG 
administration was carried out. In present study OHSS 
was noted only in 16 patients, in which 12 had mild 
and 4 had moderate form .No case of severe form was 
noted. Present results are consistent with the above 
mentioned references also showed relatively small 
percentage of complications. Homburg and Hawles 
1999 observed in a review of 1391 cycles 69% uni-
ovulatory with a relatively low prevalence of OHSS 
(1.4%) and multiple pregnancy rates of only 5.7%. 
Franks and Whilie 2002 obtained alike results within a 
single center together with 1117 treatment cycles.21 
Another study concluded that hMG in a low dosage 
protocol result in a good pregnancy rates per treated 
cycle with a low prevalence of multiple pregnancy as 
well as a low risk for OHSS. 22 
We did not expect that our treatment would be so 
much effective however, it caused a modest pregnancy 
and ovulation rates. Least side effects were seen. This 
therapy appears to offer safety, efficacy, and economic 
advantages and it is worth trying prior to moving 
towards further sophisticated or expensive 
alternatives. It is evident that with potent therapy 
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modalities, and according to the habits and needs of a 
society of accomplishment continually reformed by 
mass media, the therapy of infertility should be well-
strategic, efficient and offer outcomes within a 
satisfactory time. 
Conclusion 
1. Clomiphene Citrate with Human Menopausal 
Gonadotropins have a likely supportive 
consequences on ovulation rate contrasted to that 
of Human Menopausal Gonadotropin alone. 
2.  Ovulation induction with gonadotropin has 
turned out to be a standard element for physicians 
treating females with ovulatory dysfunction. 
Accordingly there is a chance of replacing 
Clomiphene Citrate + Human Menopausal 
Gonadotropin as first-line therapy for an-
ovulatory infertility instead of Clomiphene Citrate 
therapy alone. 
References 
1. Pinar G, Zeyneloglu HB. Quality of life, anxiety and 
depression in Turkish women prior to receiving assisted 
reproductive techniques. Int J Fertil Steril. 2012;6(1):1–12. 
2. Chowdhury MA, Haque MM, Chowdhury S, Prodhania MS. 
Determinants of infertility among couples seeking treatment 
in a selected clinic in Dhaka city. Chattagram Maa-O-Shishu 
Hospital Medical College Journal. 2014;13(3):42-45. 
3. Kreyenfeld M, Konietzka D, editors. Childlessness in Europe: 
Contexts, causes, and consequences. Springer; 2017 . 
4. Kloss JD, Perlis ML, Zamzow JA, Culnan EJ, Gracia CR. Sleep, 
sleep disturbance, and fertility in women. Sleep Medicine 
Reviews. 2015 ;22:78-87. 
5. Satir DG, Kavlak O. Use of the internet related to infertility 
by infertile women and men in Turkey. Pakistan Journal of 
Medical Ssciences. 2017;33(2):265-68. 
6. Wolf LJ. Ovulation induction. Clin Obstet Gynecol 2005; 
43(4):902-15. 
7. Cates W, Farley TM, Rowe PJ: Worldwide patterns of 
infertility: is Africa different?Lancet 1985; 2:596-98.  
8. Maheshwari A, Hamilton M, Bhattacharya S. Effect of female 
age on the diagnostic categories of infertility. Hum Reprod 
2008; 23(3):538–42 
9. Sadia S, Waqar F, Akhtar T, Sultana S. Characteristics of 
infertile patients with ovulatory dysfunction and their 
relation to body mass index. Journal of Ayub Medical College 
Abbottabad. 2009;21(3):12-16. 
10. Hamilton-Fairley D, Kiddy D, Watson H, Paterson C, Franks 
S. Association of moderate obesity with a poor pregnancy 
outcome in women with polycystic ovary treated with low 
dose gonadotrophin. Br. J. Obstet. Gynaecol. 2002; (99): 
128-31 
11. Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, 
West C, Jacobs HS. Polycystic ovary syndrome: the spectrum 
of the disorder in 1741 patients. Hum Reprod 1995; 10: 
2107-11. 
12. Mulders A.G.M.G.J.Laren J.S.E,Eijkemans M.J.C..Patient 
predictor of outcome of gonadotrphin OI in women with 
normogonadotrophic anovulatory infertility,a meta-analysis, 
Hum Reprod update 2003; 9:429-49. 
13. Maheshwari A, Stofberg L, Bhattacharya S. Effect of 
overweight and obesity on assisted reproductive technology 
- A systematic review. Hum Reprod Update 2007; 13:433-
44. 
14. Hahn S, Janssen OE, Tan S, Pleger K. Treatment of PCOS in 
adolescence, best practice and clinical endocrinology and 
metabolism, 2005; (20): 311-30 
15. GurneeIL. Crystal Advance fertility with gonadotrophin 
fertility treatment. Clin endocrinal metab 2010; 82:62-68. 
16. Homburg R, Howles CM. Low-dose gonadotrophin therapy 
for anovulatory infertility associated with polycystic ovary 
syndrome: rationale, results, reflections and refinements. 
Hum Reprod Update 1999; 5(5):493-99 
17. Mukherjee S, Sharma S, Chakravarty BN.Pregnancy rate in 
two different treatment protocols in anovulatory women 
Hum Reprod 2000; 4:235-41 
18. Ransom.B, Nicholas JW, Frank DW. Comparison of 
pregnancy rate in CC and Human Menopausal 
Ganadotrophin. J. Obstet and Gynaecol 2009; (15)7:352-57.  
19. Mulders AG,Laren JS,Eijkemans MJ. Patient predictor of 
outcome of gonadotrphin OI in women with 
normogonadotrophic anovulatory infertility,a meta-analysis, 
Hum Reprod update 2003; 9:429-49. 
20.  Ziadeh SM, Ziadeh M, Muhannad R. Pregnancy Rates Using 
CC/hMG or hMG Alone J. Obstet & Gynecol 2010; (23) 97-
101  
21. Homburg R, Howles CM. Low-dose FSH therapy for 
anovulatory infertility associated with polycystic ovary 
syndrome: rationale, results, reflections and refinements. 
Hum Reprod Update 1999; 5(5):493-99.  
22. Ioannis E, Messinis S, Spyros D.Current and future status of 
OI in PCOS, in CC resistant cases in PCOS Hum Reprod 
2007; 235-53.. 
 
